TRIAL INFORMATION
Sponsor:MetabFix Therapeutics
Therapeutic Area:Endocrinology
Phase:PHASE III
Indication:Type 2 Diabetes Mellitus
Target Enrollment:80 patients
Est. Duration:28 months
SITE INFORMATION
Site:MedPoint Clinical Research - Nashville
Principal Investigator:Dr. Sarah Chen, MD, PhD
Total FTE Capacity:12
Available FTE:1.8
Active Trials:6
Completed Trials:18
Pool Analysis
FTE Analysis
Financial
Risk Assessment
Recommendation
Patient Pool Adequacy Analysis
Assessing whether the available patient pool can support target enrollment
TOTAL POOL
0
AVAILABLE
0
0 allocated
REQUIRED
80
ADEQUACY RATIO
0.0x
Pool Utilization
Current AllocationNaN%
If This Trial AcceptedInfinity%
Pool is Insufficient
Available pool (0) is less than target enrollment (80). Consider expanding eligibility criteria or reducing target.
Pool Adequacy Score0 / 100